Abstract
Background In 2004, expert groups in North America recommended annual influenza immunization for healthy infants and toddlers aged 6–23 months with a goal of reducing high hospitalization rates (HR). We assess cost-effectiveness of this program in Canada. Methods Analysis was from third-party payer and societal perspectives in preventing hospitalization and other outcomes among 500,000 vaccinated or non-vaccinated infants/toddlers. Base-case assumptions include: 25% attack rate (AR), 1% case hospitalization rate (HR), 0.002% case fatality, vaccine effectiveness (VE) of 66%, CDN$15 per dose for vaccine and administration, half of mothers requiring 2 h from work per dose to immunize and two doses required by 100% (first year) or 33% (subsequent years) of infants/toddlers immunized. Results After the first year, infant/toddler influenza immunization costs the third-party ∼CDN$9 per day of illness averted, CDN$120 per physician visit averted, CDN$7000 per hospitalization averted, CDN$3million per death averted and CDN$450,000 per life year gained. Corresponding costs from societal perspective are ∼CDN$3, CDN$45, CDN$2500, CDN$1million and CDN$170,000. The program becomes cost-saving from the third-party perspective at AR > 55%, HR > 4%, or cost per dose (for vaccine and its administration) <CDN$6.81. From the societal perspective corresponding breakeven occurs at 28%, 2% and CDN$11.90, or when half of all mothers require no more than 1.6 h to immunize or VE is >74%. Conclusions In the base case, infant/toddler influenza immunization is not cost-saving but could become more cost-effective in settings of higher attack rate and lower immunization cost. In this context, immunization of children in daycare or other group settings should be preferentially considered. Economic analyses should routinely inform expansions to influenza immunization programs.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call